Oruka Therapeutics, Inc. (ORKA): Shareholders' Equity
$471.93M
As of 2025-12-31
$1.11B
As of 2026-06-30
+124.6%
3-year compound annual growth
+58.9%
5-year compound annual growth
+28.6%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $471.93M | +23.5% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $382.22M | +932.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $37.02M | -11.2% | 2024-02-01, Balance as of period end |
| 2022-12-31 | $41.67M | -18.4% | 2024-02-01, Balance as of period end |
| 2021-12-31 | $51.04M | +9.7% | 2023-02-24, Balance as of period end |
| 2020-12-31 | $46.52M | +511.3% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $7.61M | +26.2% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $6.03M | -41.3% | 2020-02-18, Balance as of period end |
| 2017-12-31 | $10.28M | -53.7% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $22.19M | -41.7% | 2018-03-22, Balance as of period end |
| 2015-12-31 | $38.07M | +158.3% | 2017-03-21, Balance as of period end |
| 2014-12-31 | $14.74M | -5.4% | 2016-03-17, Balance as of period end |
| 2013-12-31 | $15.58M | +436.0% | 2015-03-19, Balance as of period end |
| 2012-12-31 | $2.91M | -49.3% | 2014-03-20, Balance as of period end |
| 2011-12-31 | $5.73M | -15.3% | 2014-03-20, Balance as of period end |
| 2010-12-31 | $6.77M | -8.6% | 2014-03-20, Balance as of period end |
| 2009-12-31 | $7.41M | n/m | 2014-03-20, Balance as of period end |
| 2008-12-31 | -$38.18M | n/m | 2014-03-20, Balance as of period end |
| 2007-12-31 | -$19.69M | n/m | 2014-03-20, Balance as of period end |
| 2006-12-31 | -$5.74M | n/m | 2014-03-20, Balance as of period end |
| 2005-12-31 | -$678.0K | n/m | 2014-03-20, Balance as of period end |
| 2004-12-31 | -$619.0K | n/m | 2014-03-20, Balance as of period end |
| 2003-12-31 | -$115.0K | n/a | 2014-03-20, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $471.93M | +23.5% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $296.72M | +69.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $458.37M | n/m |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $459.60M | +48.3% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $166.95M | -3.7% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $484.65M | +58.7% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $391.48M | n/m |
Compare ORKA, VNDA, TBPH, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗